Author:
Ailawadhi Sikander,Shune Leyla,Wong Sandy W.,Lin Yi,Patel Krina,Jagannath Sundar
Funder
Janssen Pharmaceuticals Inc
Subject
Cancer Research,Oncology,Hematology
Reference69 articles.
1. Prescribing Information,2021
2. Prescribing Information,2023
3. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma;Munshi;N Engl J Med,2021
4. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;The Lancet,2021
5. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up;Martin;J Clin Oncol,2022